September 01, 2014 2:43 PM ET

Healthcare Equipment and Supplies

Company Overview of Zyomyx, Inc.

Company Overview

Zyomyx, Inc. engages in the development and commercialization of diagnostic platforms. The company offers disposable CD4 T-cell, a point-of-care test for HIV/AIDS treatment. It also provides a platform technology for cell counting. The company was founded in 1998 and is based in Fremont, California.

6519 Dumbarton Circle

Fremont, CA 94555

United States

Founded in 1998

Phone:

510-265-8000

Fax:

510-784-2569

Key Executives for Zyomyx, Inc.

Co-Founder
Age: 49
Chief Financial Officer
Director of Technology
Director of Finance and Administration
Vice President of Manufacturing Operations
Compensation as of Fiscal Year 2014.

Zyomyx, Inc. Key Developments

Zyomyx, Inc. Receives $7.5 Million from UNITAID to Commercialize its Quantitative MyT4 Point-of-Care CD4 Test

Zyomyx, Inc. has been awarded $7.5 million from UNITAID to commercialize its quantitative MyT4(TM) point-of-care CD4 test, designed to guide HIV/AIDS treatment initiation and monitoring in low- and middle-income countries. UNITAID's funding contribution is part of its strategy to speed up access to a range of new and improved technologies from a number of manufacturers for HIV/AIDS, tuberculosis and malaria for the world's most vulnerable populations. It will support field evaluations of the product, training for national HIV programs, and country-level and global regulatory filings. The Zyomyx test is the fastest point-of-care CD4 diagnostic on the market and delivers results that are equivalent to lab-based flow cytometry, the gold standard of CD4 testing. The MyT4(TM) CD4 test is commercially available receiving a CE Mark in December 2013.

Mylan, Inc. and Zyomyx, Inc. Enter into Exclusive Distribution Agreement for Innovative Point-of-Care CD4 Diagnostic Test

Mylan, Inc. announced that it has entered into an exclusive agreement with Zyomyx, Inc. for the rights to distribute Zyomyx's proprietary point-of-care (POC) CD4 T-cell count test in the developing world. CD4 count testing is a critical diagnostic component in treating HIV/AIDS, as medical professionals refer to a patient's CD4 count to determine when to begin and/or alter HIV treatment. As part of the agreement, Mylan also has made a strategic equity investment in Zyomyx. The Zyomyx POC CD4 test is currently in final stages of development and expected to launch in the near-term, pending applicable regulatory approvals. Mylan expects to distribute the portable, easy-to-use, low-cost test in the developing world alongside its broad portfolio of high quality, affordable generic antiretroviral (ARV) drugs in order to improve access to and guide HIV/AIDS treatment in resource-limited settings. To complement the exclusive agreement with Zyomyx, Mylan also announced that it has signed a Global Access Commitment with the Bill & Melinda Gates Foundation, an investor in Zyomyx. Mylan has committed to ensuring that the Zyomyx POC CD4 technology can be made available and accessible at a reasonable price in high burden HIV countries. Increasing access to affordable and effective health interventions for those in need is a priority for the foundation.

Zyomyx, Inc. Appoints Jennifer McFarlane as Chief Financial Officer

Zyomyx, Inc. has appointed Jennifer McFarlane as Chief Financial Officer (CFO). Ms. McFarlane brings 25 years of experience in finance and global investment banking. At Zyomyx, Ms. McFarlane will be responsible for financial operations, investor relations and capital raising. Prior to joining Zyomyx, Ms. McFarlane was CFO at LanzaTech, where she built infrastructure to support the company's initial sales on three continents. Previous positions also include CEO of Astia, a nonprofit accelerator focused on high-growth, women-led startups; Executive Director of Southern Pacific Petroleum, a public energy technology company in Australia; and Vice President of Investment Banking at Salomon Brothers, now Citigroup. Ms. McFarlane has also worked with the Barents Group of KPMG Consulting, providing strategic advice and M&A services to corporations and governments across seven emerging economies.

Similar Private Companies By Industry

Company Name Region
X-Ray Cassette Repair Company, Inc. United States
NexGen Medical Systems, Inc. United States
Tobii Assistive Technology, Inc. United States
Mardil Medical, Inc. United States
Advanced Cosmetic Intervention, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Zyomyx, Inc., please visit www.zyomyx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.